Trial Profile

An Open-label, Non-randomised, Fixed-sequence, Two Period, Phase I Trial to Evaluate the Effect of Different Doses of BI 456906 (Survodutide) on the Single Dose Pharmacokinetics of Bupropion, Caffeine and Midazolam on Otherwise Healthy Volunteers With Overweight or Obesity

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Survodutide (Primary) ; Bupropion; Caffeine; Midazolam
Indications Liver cirrhosis; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Focus Pharmacokinetics
Sponsors Boehringer Ingelheim

27 Jun 2025 Planned End Date changed from 12 Nov 2025 to 5 Jan 2026.
27 Jun 2025 Planned primary completion date changed from 12 Nov 2025 to 5 Jan 2026.
13 Dec 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com